Abstract
P14-06. Phase 1 safety and immunogenicity randomised controlled trial of a vaginal gp140 vaccine
Highlights
AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
We wish to determine the optimal vaccination strategies for invoking genital tract mucosal immune responses that might protect against heterosexual HIV-1 transmission
We conducted a phase 1 trial to determine whether vaginal immunisation with an HIV-1 envelope protein could produce genital tract and systemic immune responses
Summary
Phase 1 safety and immunogenicity randomised controlled trial of a vaginal gp140 vaccine. Address: 1St George's, London, UK, 2Hull York Medical School, University of York, UK, York, UK, 3Imperial College, London, UK, 4St George's, London, UK and 5Polymun Scientific, Vienna, Austria. Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):P194 doi:10.1186/1742-4690-6-S3-P194. AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
